Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms : Implications from the German Study Group for MPN Bioregistry
Inflammation-induced thrombosis represents a severe complication in patients with myeloproliferative neoplasms (MPN) and in those with kidney dysfunction. Overlapping disease-specific attributes suggest common mechanisms involved in MPN pathogenesis, kidney dysfunction, and thrombosis. Data from 1420 patients with essential thrombocythemia (ET, 33.7%), polycythemia vera (PV, 38.5%), and myelofibrosis (MF, 27.9%) were extracted from the bioregistry of the German Study Group for MPN. The total cohort was subdivided according to the calculated estimated glomerular filtration rate (eGFR, (mL/min/1.73 m2)) into eGFR1 (≥90, 21%), eGFR2 (60-89, 56%), and eGFR3 (<60, 22%). A total of 29% of the patients had a history of thrombosis. A higher rate of thrombosis and longer MPN duration was observed in eGFR3 than in eGFR2 and eGFR1. Kidney dysfunction occurred earlier in ET than in PV or MF. Multiple logistic regression analysis identified arterial hypertension, MPN treatment, increased uric acid, and lactate dehydrogenase levels as risk factors for kidney dysfunction in MPN patients. Risk factors for thrombosis included arterial hypertension, non-excessive platelet counts, and antithrombotic therapy. The risk factors for kidney dysfunction and thrombosis varied between MPN subtypes. Physicians should be aware of the increased risk for kidney disease in MPN patients, which warrants closer monitoring and, possibly, early thromboprophylaxis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancers - 13(2021), 16 vom: 13. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gecht, Judith [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 23.09.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers13164086 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329821466 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329821466 | ||
| 003 | DE-627 | ||
| 005 | 20231225205942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13164086 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329821466 | ||
| 035 | |a (NLM)34439237 | ||
| 035 | |a (PII)4086 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gecht, Judith |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms |b Implications from the German Study Group for MPN Bioregistry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.09.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Inflammation-induced thrombosis represents a severe complication in patients with myeloproliferative neoplasms (MPN) and in those with kidney dysfunction. Overlapping disease-specific attributes suggest common mechanisms involved in MPN pathogenesis, kidney dysfunction, and thrombosis. Data from 1420 patients with essential thrombocythemia (ET, 33.7%), polycythemia vera (PV, 38.5%), and myelofibrosis (MF, 27.9%) were extracted from the bioregistry of the German Study Group for MPN. The total cohort was subdivided according to the calculated estimated glomerular filtration rate (eGFR, (mL/min/1.73 m2)) into eGFR1 (≥90, 21%), eGFR2 (60-89, 56%), and eGFR3 (<60, 22%). A total of 29% of the patients had a history of thrombosis. A higher rate of thrombosis and longer MPN duration was observed in eGFR3 than in eGFR2 and eGFR1. Kidney dysfunction occurred earlier in ET than in PV or MF. Multiple logistic regression analysis identified arterial hypertension, MPN treatment, increased uric acid, and lactate dehydrogenase levels as risk factors for kidney dysfunction in MPN patients. Risk factors for thrombosis included arterial hypertension, non-excessive platelet counts, and antithrombotic therapy. The risk factors for kidney dysfunction and thrombosis varied between MPN subtypes. Physicians should be aware of the increased risk for kidney disease in MPN patients, which warrants closer monitoring and, possibly, early thromboprophylaxis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a JAK2V617F | |
| 650 | 4 | |a bleeding | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a essential thrombocythemia (ET) | |
| 650 | 4 | |a myeloproliferative neoplasms (MPN) | |
| 650 | 4 | |a polycythemia vera (PV) | |
| 650 | 4 | |a primary myelofibrosis (PMF) | |
| 650 | 4 | |a renal dysfunction | |
| 650 | 4 | |a thromboembolism | |
| 650 | 4 | |a thrombosis | |
| 700 | 1 | |a Tsoukakis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Kricheldorf, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Stegelmann, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Klausmann, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Griesshammer, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Holger |e verfasserin |4 aut | |
| 700 | 1 | |a Hollburg, Wiebke |e verfasserin |4 aut | |
| 700 | 1 | |a Göthert, Joachim R |e verfasserin |4 aut | |
| 700 | 1 | |a Sockel, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Heidel, Florian H |e verfasserin |4 aut | |
| 700 | 1 | |a Gattermann, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Maintz, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Ali, Haifa K |e verfasserin |4 aut | |
| 700 | 1 | |a Platzbecker, Uwe |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Hänel, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Parmentier, Stefani |e verfasserin |4 aut | |
| 700 | 1 | |a Bommer, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Pahl, Heike L |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Fabian |e verfasserin |4 aut | |
| 700 | 1 | |a Kirschner, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Isfort, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Brümmendorf, Tim H |e verfasserin |4 aut | |
| 700 | 1 | |a Döhner, Konstanze |e verfasserin |4 aut | |
| 700 | 1 | |a Koschmieder, Steffen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 13(2021), 16 vom: 13. Aug. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:16 |g day:13 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers13164086 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 16 |b 13 |c 08 | ||